Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110

EpCAM nuclear localization identifies aggressive Thyroid Cancer and is a marker for poor prognosis

(2010) Ranju Ralhan et al.   BMC CANCER

Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3) as a targeted cancer immunotherapy

(2010) Diane Seimetz et al.   CANCER TREATMENT REVIEWS

Initial activation of EpCAM cleavage viacell-to-cell contact

(2009) Sabine Denzel et al.   BMC CANCER

The Emerging Role of EpCAM in Cancer and Stem Cell Signaling

(2009) M. Munz et al.   CANCER RESEARCH

Mode of cytotoxic action of T cell-engaging BiTE antibody MT110

(2009) Cornelia Haas et al.   IMMUNOBIOLOGY

Value and Limitations of Measuring HER-2 Extracellular Domain in the Serum of Breast Cancer Patients

(2009) Alexandra F. Leary et al.   JOURNAL OF CLINICAL ONCOLOGY

Potent Control of Tumor Growth by CEA/CD3-bispecific Single-chain Antibody Constructs That Are Not Competitively Inhibited by Soluble CEA

(2009) Ralf Lutterbuese et al.   JOURNAL OF IMMUNOTHERAPY

Nuclear signalling by tumour-associated antigen EpCAM

(2009) Dorothea Maetzel et al.   NATURE CELL BIOLOGY

A genome-wide expression analysis identifies a network of EpCAM-induced cell cycle regulators

(2008) K Maaser et al.   BRITISH JOURNAL OF CANCER